Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Novartis
Vanderbilt-Ingram Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
Marker Therapeutics, Inc.
TC Biopharm
Sanofi
Institut Curie
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
Medical College of Wisconsin
Syros Pharmaceuticals
Gruppo Italiano Malattie EMatologiche dell'Adulto
University of Florida
Fred Hutchinson Cancer Center
Washington University School of Medicine
Ensoma
Astex Pharmaceuticals, Inc.
Loyola University
Fred Hutchinson Cancer Center
University Hospital Regensburg
Technische Universität Dresden
Weill Medical College of Cornell University
SCRI Development Innovations, LLC
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
M.D. Anderson Cancer Center
University of Nebraska
Fred Hutchinson Cancer Center
University of California, San Diego
Dana-Farber Cancer Institute
Emory University
Washington University School of Medicine
Wake Forest University Health Sciences
Memorial Sloan Kettering Cancer Center
Brown University
University of Jena
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Therapeutic Advances in Childhood Leukemia Consortium
Technische Universität Dresden
Nohla Therapeutics, Inc.
University of Chicago
Abramson Cancer Center at Penn Medicine
Milton S. Hershey Medical Center
Masonic Cancer Center, University of Minnesota
NYU Langone Health